Overview

(Hyoscine Butylbromide) for Abdominal Pain Associated With Cramping on Demand Basis

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The primary objective of this pilot study is to assess effects of Hyoscine Butylbromide (HBB) 20 mg in comparison to placebo, when used as needed, as measured by the subject's assessment of intensity of abdominal pain associated with cramping (APC) in the treatment of two episodes.
Phase:
Phase 2
Details
Lead Sponsor:
Boehringer Ingelheim
Treatments:
Butylscopolammonium Bromide
Scopolamine Hydrobromide